Receptor News and Research

RSS

Scientists identify molecular mechanism central to development of osteoarthritis pain

Researchers at Rush University Medical Center, in collaboration with researchers at Northwestern University, have identified a molecular mechanism central to the development of osteoarthritis (OA) pain, a finding that could have major implications for future treatment of this often-debilitating condition.

28 Dec 2012

Manipulating transcription factor can change subtype of breast cancer

Australian scientists have shown how a 'transcription factor' causes breast cancer to develop an aggressive subtype that lacks sensitivity to oestrogen and does not respond to anti-oestrogen therapies such as Tamoxifen and aromatase inhibitors.

28 Dec 2012

Genetic differences in enzyme CYP2D6 play a key role in effectiveness of tamoxifen for breast cancer

For nearly a decade, breast cancer researchers studying the hormone therapy tamoxifen have been divided as to whether genetic differences in a liver enzyme affect the drug's effectiveness and the likelihood breast cancer will recur.

27 Dec 2012

Study suggests genetic component in pain response among children

At least two common gene variants are linked to "clinically meaningful" differences in pain scores in children after major surgery, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).

25 Dec 2012

Antibody type prognostic for myasthenia gravis patients

Patients who have myasthenia gravis are more likely to have a severe form of the disease and more difficulty achieving remission if they are seropositive for antibodies to muscle-specific kinase, report researchers.

24 Dec 2012

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

OncoMed Pharmaceuticals, Inc., a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that patient dosing has begun in a Phase 1 clinical trial of OMP-52M51 in patients with hematologic cancers.

21 Dec 2012

Molecule imitating a virus may trigger inappropriate immune response

Why would our immune system turn against our own cells? This is the question that the combined Inserm/CNRS/ Pierre and Marie Curie University/Association Institut de Myologie have strived to answer in their "Therapies for diseases of striated muscle", concentrating in particular on the auto-immune disease known as myasthenia gravis.

21 Dec 2012

Researchers create first ever atlas of immune cells in the human body

By analyzing tissues harvested from organ donors, Columbia University Medical Center (CUMC) researchers have created the first ever "atlas" of immune cells in the human body.

21 Dec 2012

Androgen deprivation therapies may have adverse effects in men with precancers

The use of androgen deprivation therapies to prevent precancerous prostate abnormalities developing into aggressive prostate cancer may have adverse effects in men with precancers with specific genetic alterations, according to data from a preclinical study recently published in Cancer Discovery, a journal of the American Association for Cancer Research.

21 Dec 2012

Combination of diet and exercise may prevent breast cancer in obese, postmenopausal women

Obese, postmenopausal women are at greater risk for developing breast cancer and their cancers tend to be more aggressive than those in lean counterparts.

20 Dec 2012

Study identifies mechanisms responsible for regenerating blood vessels in the brain

New research from the University of Georgia identifies the mechanisms responsible for regenerating blood vessels in the brain.

20 Dec 2012

Study focuses on hormone-sensitive breast tumours

Gene expression in breast cancer provides valuable biological information for better determining the diagnosis, treatment, risk of relapse and survival rate. However, the most common form of characterizing breast cancer is by histopathological techniques. This study, headed by Dr Aleix Prat, Head of the Translational Genomics Group at the Vall d'Hebron Institute of Oncology (VHIO) and an oncologist at the Breast Cancer Unit of the Vall d´Hebron University Hospital, focused on hormone-sensitive breast tumours known as luminals.

20 Dec 2012

Biologic changes after delivery may prevent development of chronic pain

Chronic pain from childbirth is remarkably rare, according to a study from the January issue of Anesthesiology. Additionally, in a second study, researchers at Wake Forest School of Medicine, Winston-Salem, N.C., found the biologic changes after delivery may prevent the development of pain.

19 Dec 2012

Cytokine rise signals RCC progression

Progression of renal cell carcinoma is frequently preceded by a rise in levels of proangiogenic cytokines, Italian researchers have found.

17 Dec 2012

Human nociception genes mapped out

Researchers have uncovered a “network map” of genes that are involved in pain perception, which they say may help identify new analgesic drugs.

17 Dec 2012

Naurex announces completion of $38M Series B financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of a $38 million Series B financing led by new investor Baxter Ventures.

17 Dec 2012

New technique could help develop more-specific, cell-based immune therapies for cancer

A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer.

17 Dec 2012

Five young investigators receive prestigious grants at IOF’s 3rd Asia-Pacific Osteoporosis Meeting

Five young investigators from the Asia-Pacific region have been awarded prestigious grants on the closing day the IOF Regionals - 3rd Asia-Pacific Osteoporosis Meeting, a major medical conference organized by the International Osteoporosis Foundation (IOF) in Kuala Lumpur.

16 Dec 2012

Study describes new, paradoxical characteristics of HER2-negative breast cancer

A multicenter study led by researchers at UC Davis describes new, paradoxical characteristics of the most common type of breast cancer. The findings shed light on how the disease can evade treatment and could improve diagnosis and treatment of breast cancer.

15 Dec 2012

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

An international study of ibrutinib in people with relapsed or refractory mantle cell lymphoma (MCL) continues to show unprecedented and durable results with few side effects.

15 Dec 2012

Receptor News and Research

Scientists identify molecular mechanism central to development of osteoarthritis pain

Manipulating transcription factor can change subtype of breast cancer

Genetic differences in enzyme CYP2D6 play a key role in effectiveness of tamoxifen for breast cancer

Study suggests genetic component in pain response among children

Antibody type prognostic for myasthenia gravis patients

OncoMed commences dosing in OMP-52M51 Phase 1 clinical trial for hematologic cancers

Molecule imitating a virus may trigger inappropriate immune response

Researchers create first ever atlas of immune cells in the human body

Androgen deprivation therapies may have adverse effects in men with precancers

Combination of diet and exercise may prevent breast cancer in obese, postmenopausal women

Study identifies mechanisms responsible for regenerating blood vessels in the brain

Study focuses on hormone-sensitive breast tumours

Biologic changes after delivery may prevent development of chronic pain

Cytokine rise signals RCC progression

Human nociception genes mapped out

Naurex announces completion of $38M Series B financing

New technique could help develop more-specific, cell-based immune therapies for cancer

Five young investigators receive prestigious grants at IOF’s 3rd Asia-Pacific Osteoporosis Meeting

Study describes new, paradoxical characteristics of HER2-negative breast cancer

Ibrutinib continues to show unprecedented results in patients with mantle cell lymphoma

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News